Suppr超能文献

细胞因子吸附疗法在淋巴瘤相关噬血细胞性淋巴组织细胞增多症和异基因造血干细胞移植中的应用。

Cytokine adsorption therapy in lymphoma-associated hemophagocytic lymphohistiocytosis and allogeneic stem cell transplantation.

机构信息

Department of Nephrology and Rheumatology, University Medical Center Göttingen, Robert-Koch-Str. 40, 37075, Göttingen, Germany.

Department of Hematology and Medical Oncology, University Medical Center Göttingen, Göttingen, Germany.

出版信息

J Artif Organs. 2021 Sep;24(3):402-406. doi: 10.1007/s10047-020-01244-2. Epub 2021 Jan 18.

Abstract

Lymphoma-associated Hemophagocytic lymphohistiocytosis (HLH) represents a severe complication of disease progression, mediated through cytokine release from the lymphoma cells. Cytokine adsorption may contribute as a supportive treatment to stabilize organ function by reduction of cytokine levels. So far, no experiences of cytokine adsorption and simultaneous stem cell transplantation were published. We report the case of a patient with aggressive lymphoma secondary to chronic lymphocytic leukemia with rapidly progressive HLH (Richter's transformation) upon conditioning chemotherapy prior to allogeneic stem cell transplantation (ASCT). Continuous hemodiafiltration was initiated in the treatment of shock with acute renal failure, lactacidosis and need for high-dose catecholamine therapy, integrating an additional cytokine-adsorbing filter (CytoSorb®) to reduce cytokine levels. This was followed by scheduled allogenic stem cell transplantation. We observed a marked decrease in interleukin-6 plasma levels, associated with a reduced need for vasopressor therapy and organ function stabilization. Hematopoietic engraftment was present at day 14 post-ASCT, leading to disease-free discharge at day 100 post-transplantation. Cytokine adsorption may serve as a safe adjunct to HLH/sepsis treatment during allogeneic stem cell transplantation. Clinical studies are required to make future treatment recommendations.

摘要

淋巴瘤相关噬血细胞性淋巴组织细胞增生症 (HLH) 是疾病进展的严重并发症,通过淋巴瘤细胞释放细胞因子介导。细胞因子吸附可能通过降低细胞因子水平作为支持治疗来稳定器官功能。迄今为止,尚无细胞因子吸附和同时进行干细胞移植的经验发表。我们报告了一例继发于慢性淋巴细胞白血病的侵袭性淋巴瘤患者,在异基因干细胞移植 (ASCT) 前的预处理化疗中出现快速进展的 HLH(里希特转化)伴噬血细胞性淋巴组织细胞增生症。在休克合并急性肾功能衰竭、乳酸性酸中毒和需要大剂量儿茶酚胺治疗时,我们开始进行连续性血液透析滤过,同时加入额外的细胞因子吸附过滤器 (CytoSorb®) 以降低细胞因子水平。随后进行了计划的异基因干细胞移植。我们观察到白细胞介素-6 血浆水平明显下降,同时减少了血管加压素治疗的需求和器官功能的稳定。ASCT 后第 14 天出现造血植入,移植后第 100 天无疾病出院。细胞因子吸附可作为异基因干细胞移植期间 HLH/脓毒症治疗的安全辅助手段。需要进行临床研究以提出未来的治疗建议。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7b76/8380562/f80167255c50/10047_2020_1244_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验